Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 16/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173547 | 0.92 | IGF1R (0.39) | IGF1RLMNANTRK1P2RX3 | |
| SCHEMBL6169483 | 0.91 | IGF1R (0.38) | IGF1RLMNANTRK1P2RX3 | |
| SCHEMBL6175508 | 0.89 | IGF1R (0.39) | IGF1RLMNA | |
| SCHEMBL6174070 | 0.88 | IGF1R (0.39) | IGF1RLMNA | |
| SCHEMBL6173990 | 0.85 | IGF1R (0.39) | IGF1RLMNA | |
| SCHEMBL6173161 | 0.84 | IGF1R (0.37) | IGF1RLMNANTRK1 | |
| SCHEMBL6175260 | 0.83 | IGF1R (0.39) | IGF1RLMNA | |
| SCHEMBL6175512 | 0.82 | IGF1R (0.37) | IGF1RLMNA | |
| SCHEMBL6173968 | 0.82 | IGF1R (0.35) | IGF1RLMNA | |
| SCHEMBL6171076 | 0.82 | LMNA (0.48) | IGF1RLMNANTRK1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599464-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004070050-A2 | CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | WO | disclosed |